Drug Formulation Innovations Are Driving the Liposome Drug Delivery...

Drug Formulation Innovations Are Driving the Liposome Drug Delivery Market

Posted 2024-05-16 12:04:30

708

Liposome drug delivery involves encapsulating drugs in liposomes, which are nanosized vesicles made of phospholipid bilayers, for safer and more effective delivery of active pharmaceutical ingredients. Drugs can be entrapped inside the aqueous core or integrated into the phospholipid bilayers of liposomes. This modifying drug formulations allows for controlled or sustained release of drugs at target sites. It also helps protect drugs from degradation and prevents harmful side-effects by reducing interactions with healthy tissues. Some key advantages of liposome drug delivery include reduced toxicity, few side effects, improved solubility of water-insoluble compounds, and better bioavailability of encapsulated drugs. The growing demand for advanced drug delivery systems to improve patient outcomes is driving innovations in liposomal formulations.

The Global Liposome Drug Delivery Market is estimated to be valued at US$ 9,935.6 Mn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the Liposome Drug Delivery Market Size are Gilead Sciences, Inc., Luye Pharma Group, Ipsen Biopharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Acuitas Therapeutics, LIPOSOMA B.V., Takeda Pharmaceutical Company Limited, Taiwan Liposome Company, Ltd., Endo International, and Jazz Pharmaceuticals plc. Gilead Sciences holds a significant market share due to its leading liposomal drug Ambisome for fungal infections.

The growing demand for targeted and controlled drug delivery along with the rising prevalence of cancer and infectious diseases is boosting the liposome drug delivery market. Liposomal formulations help deliver high concentrations of drugs directly to diseased sites while avoiding toxic accumulation in healthy tissues.

Major players are expanding their geographical footprint to capture the potential of emerging markets. Taiwan Liposome Company recently partnered with Trigo to commercialize liposomal drugs in China. LIPOSOMA entered into an agreement with Enzychem for development and commercialization of liposome products in Southeast Asia, Africa, and Latin America. The global expansion will help address the growing needs of patients worldwide.
Get more insights on Liposome Drug Delivery Market